Skip to main content
. 2011 Dec 29;3(3):649–653. doi: 10.3892/ol.2011.543

Figure 2.

Figure 2

Immunohistochemical analyses of EGFR, KRAS and GSTP. (A) Negative immunoreactivity for EGFR at the primary lesion and (B) positive immunoreactivity at the site of lung metastasis in case 7, (C) negative immunoreactivity for KRAS (G12D) at the primary lesion and (D) positive immunoreactivity for KRAS (G12D) at the site of lung metastasis in case 5, (E) immunoreactivity for GSTP is denoted by (++) at the primary lesion, (F) (+++) at the site of liver metastasis, and (G) (−) at the site of lung metastasis in case 5; all sites had the same KRAS G12D mutation. EGFR, epidermal growth factor receptor; GSTP, glutathione S-transferase II; G12D, glycine to aspartic acid mutation at codon 12.